Jasper Therapeutics (NASDAQ:JSPR) Shares Gap Down – Time to Sell?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) gapped down prior to trading on Friday. The stock had previously closed at $14.0760, but opened at $12.76. Jasper Therapeutics shares last traded at $15.8740, with a volume of 47,986 shares traded.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wall Street Zen raised Jasper Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. William Blair started coverage on Jasper Therapeutics in a research report on Wednesday, October 14th. They set an “outperform” rating for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Piper Sandler initiated coverage on shares of Jasper Therapeutics in a research note on Wednesday, August 12th. They set an “overweight” rating and a $60.00 target price for the company. Finally, HC Wainwright restated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Jasper Therapeutics has a consensus rating of “Hold” and a consensus target price of $220.00.

Jasper Therapeutics Stock Up 14.0%

The company has a market capitalization of $534.13 million, a price-to-earnings ratio of -10.03 and a beta of 3.30. The company’s 50 day simple moving average is $0.58 and its two-hundred day simple moving average is $0.84.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Friday, August 14th. The company reported ($3.00) earnings per share for the quarter, topping the consensus estimate of ($8.03) by $5.03. Analysts anticipate that Jasper Therapeutics, Inc. will post -0.94 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.